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Abstract
One needs to think outside of the box, as one of us (Ronald B Luftig) learned from many years as
a mathematician, and a biophysicist.
In this short Review, the need to focus on producing high levels of neutralizing antibodies (NAbs)
to incoming and conformationally altered virus after it has bound to CD4+ cells is essential.
Increasing the number of gp120 molecules on the surface of L-2 particles, could allow for an
enhanced number of NAbs.
The attempt at increasing CD8+ T cell responses in recent vaccine trials has not worked perhaps
because it may have allowed HIV to enter into remote sanctuaries. Our approach focuses on
increasing NAbs, before high levels of CD8+ T cells are produced.
Background
It has now become a frequent ritual to read of the newest
clinical trial failure and yet the same paradigm goes on
[1]. Most recently the promising Phase III trial termed
STEP, started in December 2004 was stopped [2]. The
strategy was to boost killer T-cells in order to provide a
broad-based vaccine and protect high-risk individuals
against HIV strains world-wide. An adenovirus vector
shuttled 3 HIV genes into the body. Surprisingly, there
were more HIV infections in the vaccinees as compared to
those in the placebo group [3].
Despite this set-back, trials are starting this Fall using a
similar strategy. What is wrong is that vaccinology is not
only a science but an art and one needs to take a step back
from using the same failed approaches.
We propose that one needs to think differently by present-
ing defective HIV particles (L-2) which contain 7 to 10-
fold more gp120 spikes on their surface in a prime (plas-
mid pL2)-boost (L-2 particle-Figure 1) strategy. These par-
ticles are unique in that they lack several core components
of mature virions and present an increased number of
gp120 particles (trimeric spikes) as compared to wild type
(Table 1). Although mechanistically unclear the increase
in surface ENV on these particles is likely due to stabiliza-
tion of the trimers in the membranes by mutations in the
gp41 C-terminus [4] and possibly due to a truncated 56
amino acid NH2 terminal Nef (STOP codon exactly at
cleavage site of HIV protease in wild type virus). Prelimi-
nary cryo-electron microscopic analysis of L-2 (Figure 2A)
relative to HIV (Figure 2B) shows enhanced gp120 spikes
(Figure 2A, red arrows) which substantiates the TEM
images (Figure 1) and immunoblotting studies that
detailed the enrichment of Env on L-2 [5] and pL2 [6]. The
double membrane of immature gag in L-2 particles noted
by Wright, et al [7] in HIV is also clearly visible (Figure 2,
blue arrows). We thank the Lab of Dr. Kenneth Roux for
Published: 19 December 2007
Journal of Immune Based Therapies and Vaccines 2007, 5:12 doi:10.1186/1476-8518-5-
12
Received: 6 December 2007
Accepted: 19 December 2007
This article is available from: http://www.jibtherapies.com/content/5/1/12
© 2007 Zhong and Luftig; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Immune Based Therapies and Vaccines 2007, 5:12 http://www.jibtherapies.com/content/5/1/12
Page 2 of 4
(page number not for citation purposes)
contributing Figure 2, using a cryo-EM method they devel-
oped to observe enhanced numbers of spikes on an SIV
gp41 mutant [8].
Therefore we propose that recombinant L-2 particles will
be an excellent scaffold for the presentation of native Env
trimers. This approach allows for the flexibility of a)
building multi-clade Env expressing particles. The new
constructs would include Clades C, AE and circulating
recombinant forms (CRFs) from China and Africa [9,10]
Envs in pL2. Currently, we are testing Clades C and AE to
verify that the L-2 backbone for these new Clades still
allows for the large number of trimers per particle
observed with L-2. If this doesn't work, we will use a dif-
ferent consensus Env expression construct [11] or b) insert
structure-based snapshots [12]. It is plausible that these
approaches will improve upon current vaccine immuno-
gens by displaying Env trimers in their native context and
through stabilized multimerization of Env antigen on L-2
particles.
Simultaneously an intranasal spray is to be administered
in order to protect CD4 T-cells in the GALT. The rapid tar-
geting of HIV to the gut mucosa has been well demon-
strated in monkeys and recent results show it is only
necessary but not sufficient for disease [13].
The properties of L-2 particles are depicted in Table 1
(detailed sequencing manuscript of this data submitted by
Zhong, Ikuta and Luftig).
In the model proposed we are thinking about HIV vacci-
nation in a different way. It is important to elicit neutral-
izing antibodies [14], protect destruction of the GALT and
COMBINE this with a potent CTL-based vaccine compo-
Cryo-EM images: A) The L-2 images show many envelope spikes (red arrows) and a double membrane (blue arrows) Figure 2
Cryo-EM images: A) The L-2 images show many envelope spikes (red arrows) and a double membrane (blue arrows). B) The 
control HIV shows few envelope spikes and a single membrane (blue arrow).
The cartoon of the L-2 particle has 7–10 times more enve- lope spikes compared to HIV and shows the double mem- brane of immature gag Figure 1
The cartoon of the L-2 particle has 7–10 times more enve-
lope spikes compared to HIV and shows the double mem-
brane of immature gag. Inside the picture is a TEM image of 
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nent. The recent STEP failure further strengthens this triad
approach as many T-cell based parameters scored high
with the vaccine candidate. We believe this novel
approach for elicitation of broadly neutralizing antibod-
ies is the key to its success. However, thus far, no single
immunogen has been capable of eliciting a broadly neu-
tralizing response in vivo [11]. Most candidates have
relied on mimics of the epitopes recognized by the hand-
ful of potent broadly neutralizing antibodies. While rea-
sonable in concept, these approaches have not succeeded.
Several years ago, Drs. Ikuta and Goto discovered a sub-
line of HIV-infected cells producing protease deficient
defective particles that they called L-2 ([5] and Fig 1). Fig-
ure 1 displays a cartoon of L-2 and shows a TEM with sev-
eral particles containing multiple spikes inside the
cartoon. We suggested to Dr. Ikuta that L-2 looked exactly
like the doughnut shaped, protease deficient mutants of
retroviruses we had studied in the murine system; he con-
sidered it was a mutant in RT, since there was no measur-
able RT activity. Our labs then both sequenced the PR
gene nucleic acid from L-2 cells using RT-PCR and found
a T nucleotide insertion about one third from the NH2
terminus equivalent of the gene, leading to a STOP codon
several nucleotides distant. Thus, there was no PR, RT or
INT activity. When the genome of L-2 was sequenced in
1997 it was found that there were 5 mutations [15]. This
formed the basis of a patent I received [16]. In 2007 a
complete RT-PCR derived DNA sequencing of L-2 parti-
cles and its plasmid pL2 was performed. As noted, L-2 par-
ticles are unique in that they lack several core components
of mature virions. An additional three mutations were
found in 2007 (Table 1).
After many years we learned from monkey studies per-
formed by the New England Primate and Harvard groups
that mutated SIV will eventually revert back to wild type.
However, L-2 particles have 8 mutational differences from
HIV (embodied in the 5 differences noted in Table 1). All
are related structurally and provide a lock and key effect
that might slow down reversions until broad memory B
and T-cells responses are generated. Protection of the
GALT and provision of a potent CTL-based component
would complement these events.
Further, if a high risk individual is infected with a new
CRF or Clade other than B, this may be solved by con-
structing through cassette mutagenesis; multiple new par-
ticles based on a backbone of L-2 defective mutant
plasmid DNAs mixed together.
AIDS researchers may reasonable argue, that even if mul-
tiple broadly neutralizing antibodies did exist, once a high
risk patient was infected with HIV, it could avoid neutral-
ization or CTL killing and enter into DNA quiescent T-
cells and re-emerge unscathed. However, by an unknown
mechanism if L-2 RNA is present within T-cells it serves as
a stealth agent and wild type HIV picks up the L-2 enve-
lope with multiple gp120 spikes [17]. This further
enhances an opportunity in the body for HIV to be neu-
tralized by pre-existing broadly neutralizing sera or CTL's.
Finally, of great concern is that we don't want to repeat the
errors of other excellent AIDS researchers and grow the
virus in human T-cell lines, which pick up MHC Class I, II
and other components. Thus, L-2 which originated in a
human T cell line is being grown in non-human cell lines.
In addition, a recent paper [18] refers to the possibility
that if potent T-cell responses are boosted, HIV may move
to a sanctuary resulting in persistence of the virus.
The reason for writing this article is not to guarantee an
HIV/AIDS vaccine, but to stimulate new thinking for such
a vaccine.
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